%PDF-1.4
%
80 0 obj
<>
endobj
77 0 obj
<>
endobj
135 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T12:43:13Z
2024-03-28T17:40:38-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T17:40:38-07:00
application/pdf
Heather
2002-24.oct
uuid:10a7c2ca-1dd2-11b2-0a00-b20927fd5800
uuid:10a7c2cc-1dd2-11b2-0a00-6a0000000000
endstream
endobj
66 0 obj
<>
endobj
67 0 obj
<>
endobj
81 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
166 0 obj
[170 0 R]
endobj
167 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(7.)-875 (Pincus )17.8 (T)74 (. )17.8 (The paradox of ef)17.8 (fective therapies but poor long-term)]TJ
1.675 -1.25 Td
[(outcomes in rheumatoid arthritis. Semin )54.8 (Arthritis Rheum)]TJ
0 Tw 0 -1.25 TD
(1992;21:2-15.)Tj
0.0249 Tw -1.675 -1.25 Td
[(8.)-875 (Hawley DJ, )17.7 (W)79.8 (olfe F)79.8 (. )54.8 (Are the results of controlled clinical trials and)]TJ
1.675 -1.25 Td
(observational studies of second line therapy in rheumatoid arthritis)Tj
T*
(valid and generalizable as measures of rheumatoid arthritis)Tj
T*
[(outcome \227 )54.9 (Analysis of 122 studies. J Rheumatol 1991;18:1008-14.)]TJ
-1.675 -1.25 Td
[(9.)-875 (Fries J. Ef)17.8 (fectiveness and toxicity considerations in outcome)]TJ
1.675 -1.25 Td
(directed therapy in rheumatoid arthritis. J Rheumatol 1996;23)Tj
T*
(Suppl 44:102-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, Kraines RG. Measurement of patient outcomes)]TJ
0 Tc 2.175 -1.25 Td
[(in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Ramey DR, Fries J, Singh G. )17.7 (The Health )54.8 (Assessment Questionnaire)]TJ
0 Tc 2.1381 -1.25 Td
[(1995 \227 Status and review)64.9 (. In: Spilker B, editor)54.9 (. Quality of life and)]TJ
T*
(pharmacoeconomics in clinical trials. 2nd ed. Philadelphia:)Tj
T*
(Lippincott-Raven Publishers; 1995.)Tj
-2.175 -1.25 Td
[(12.)-875 (Hawley DJ, )17.7 (W)79.8 (olfe F)79.8 (. Sensitivity to change of the Health)]TJ
-0.00011 Tc 2.175 -1.25 Td
(Assessment Questionnaire \(HAQ\) and other clinical and health)Tj
T*
(status measures in rheumatoid arthritis: Results of short term)Tj
0 Tc T*
(clinical trials and observational studies versus long term)Tj
-0.00011 Tc T*
[(observational studies. )54.8 (Arthritis Care Res 1992;5:130-6.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (W)79.7 (olfe F)79.7 (,)-0.1 ( )54.8 (Anderson J, Hawley DJ. Rates and predictors of work)]TJ
0 Tc 2.175 -1.25 Td
(disability in rheumatoid arthritis: importance of disease and)Tj
-0.00011 Tc T*
[(psycho-social and work place factors. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1994;37:231-6.)Tj
0.0249 Tw -2.175 -1.25 Td
[(14.)-875 (W)79.8 (olfe F)79.8 (, Cathey MA. )54.8 (Analysis of methotrexate treatment ef)17.8 (fect in a)]TJ
2.175 -1.25 Td
(longitudinal observational study \227 Utility of cluster analysis. )Tj
T*
(J Rheumatol 1991;18:672-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Singh G, Morfeld D, Shi H, Ramey DR, Fries J. Ef)17.7 (fectiveness and)]TJ
0 Tc 2.175 -1.25 Td
[(toxicity profiles of drug treatment in RA)-220.1 ([abstract]. )54.8 (Arthritis Rheum)]TJ
T*
(1994;37:Suppl: S196.)Tj
-2.175 -1.25 Td
[(16.)-875 (van der Heide )54.8 (A, Jacobs JWG, Schenk )36.8 (Y)129.1 (, Bijlsma JWJ. Endpoint)]TJ
2.175 -1.25 Td
(measures in rheumatoid arthritis clinical trials: Group summary and)Tj
T*
(individual patient analysis. J Rheumatol 1994;21:2195-9.)Tj
30.825 41.25 Td
[(17.)-875 (Eberhardt KB, Fex E. Functional impairment and disability in early)]TJ
2.175 -1.25 Td
(rheumatoid arthritis \227 development over 5 years. J Rheumatol)Tj
0 Tw T*
(1995;22:1037-42.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (W)79.8 (ard MM. Clinical measures in rheumatoid arthritis: )17.7 (Which are)]TJ
2.175 -1.25 Td
(most useful in assessing patients? J Rheumatol 1994;21:17-21.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Ortendahl M, Schettler J, Fries JF)79.7 (. Factors influencing length of)]TJ
0 Tc 2.175 -1.25 Td
(time taking methotrexate in rheumatoid arthritis. J Rheumatol)Tj
0 Tw T*
[(2000;27:1)36.9 (139-47.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
0 Tc T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Sherrer )36.8 (YS, Bloch DA, Mitchell DM, )36.8 (Y)100 (oung DY)128.8 (, Fries JF)79.7 (. )17.7 (The)]TJ
0 Tc 2.175 -1.25 Td
[(development of disability in rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1986;29:494-500.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Scott DL, Symmons DPM, Coulton BL, Popert )54.8 (AJ. Long-term)]TJ
0 Tc 2.175 -1.25 Td
(outcome of treating rheumatoid arthritis: result after 20 years.)Tj
T*
[(Lancet 1987;1:1)36.9 (108-1)36.9 (1.)]TJ
-2.175 -1.25 Td
[(23.)-875 (W)79.8 (ard MM, Fries JF)79.8 (. )17.7 (T)34.9 (rends in anti-rheumatic medication use)]TJ
2.175 -1.25 Td
(among patients with rheumatoid arthritis, 1981-1996. J Rheumatol)Tj
0 Tw T*
(1998;25:408-16.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Alarcon GS, )17.7 (T)34.8 (racy IC, Strand GM, Singh K, Macaluso M. Survival)]TJ
0 Tc 2.175 -1.25 Td
[(and drug discontinuation analyses in a lar)17.8 (ge cohort of methotrexate)]TJ
T*
[(treated rheumatoid arthritis patients. )54.9 (Ann Rheum Dis 1995;)]TJ
0 Tw T*
(54:708-12.)Tj
0.0249 Tw -2.175 -1.25 Td
[(25.)-875 (W)79.8 (ard MM, Leigh P)110.8 (,)0.1 ( Fries JF)79.8 (. Progression of functional disability in)]TJ
2.175 -1.25 Td
[(patients with rheumatoid arthritis. )54.8 (Associations with rheumatology)]TJ
T*
[(subspecialty care. )54.9 (Arch Intern Med 1993;153:2229-37.)]TJ
-2.175 -1.25 Td
[(26.)-875 (Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis \227 )54.9 (A)-219.8 (life table review of 587 patients treated in)]TJ
T*
(community practice. J Rheumatol 1993;20:639-44.)Tj
-2.175 -1.25 Td
[(27.)-875 (Fries JF)79.8 (, )17.7 (W)39.8 (illiams CA, Singh G, Ramey DR. Response to therapy)]TJ
2.175 -1.25 Td
[(in rheumatoid arthritis is influenced by immediately prior therapy)64.9 (. )]TJ
T*
(J Rheumatol 1997;24:838-44.)Tj
ET
0 0 0 0 scn
420 777 137 -27 re
f*
408 770 150 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Ortendahl, et al: MTX r)36.9 (esponse in RA)]TJ
0 Tw 60.9375 -0.0313 Td
(2091)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
104 0 obj
<>
endobj
140 0 obj
<>
endobj
87 0 obj
<>
endobj
83 0 obj
<>
endobj
85 0 obj
<>
endobj
98 0 obj
<>stream
HVpMg}9ބ(yȃsHInMzInz
Iq<McRa2Ue.2mXձmHֶɴvztMcZAYܳsT;/|s 5P7Ō^u
Ԏ-W6`\\P?sq4mʙ^`G3_^\vcAY@t02_JS3P=ʩ8 _RV^pQΞ( .0m
l6P? %>_9wB-(_ Q, kT W"+;XgKI[q a ׯݑVCA!.z@bV␋9"r_2XKP)ȢXx Gp18$S
8!>Uk-#=~v!T7!X͘QA^o:żh8yn.X"E>=Ǔ&q^&s}0@yWc56ABʶY_ٽ1''h=1IFZݬVuboX
I=C0qb&jqEDAbqX^ŭPQZW.YgM*Y 5 x
wD&lU&d+TE]^HvJ%͑Ϻ ػud!;sBN&FI~߈2RHC4e2W=^ּOVUhͳ>cy]0K{2xo.'ɳAxd!8E"GpjC<1^TF,oZr+>GY\Y %r\!V$Qs"uMתm[i`"TZbmCC{`GˑǛ63P2aoYM#d>]:NpxPYμϩ3eFE(S41]r1O&*Z*v⠸&n;ldtv&Wsy*d\!ߖʍ=]Erj:NVQg9~:h -_+hh]^ۣ;9L|ݹҹY->DlDzIzqYer cE8ķO\'fB6
ID5Kֵ߽pi(]}uFa|фjto ճG?K%)1!s\lLttj.m0CS)5r|3c-~*PL}LrӟгWOcO`w5t)DdZ ՔЎ7<[7O9U/;bԷ#/)d{xx#kv6C6%/1x\Bw)&fȦ3td1>N 0×Qb>Ckd]{">ZyWє9@KjD%jJ^S./,0rm6$J
pcQc&&,v퉏4ZRꁉ|!(g';?mq7-by+nie-Sۆ]